IRL 1620 peptide

IRL 1620 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Suc-DEEAVYFAHLDIIW, Asp-1 is succinylated

Suc-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp-OH

14

95.5%

C₈₆H₁₁₇N₁₇O₂₇

1820.0

Synthetic

Powder

IRL 1620 is an N-succinylated endothelin-1 analogue which acts as a highly selective ETB endothelin receptor agonist, with Ki values of 0.016 and 1900 nM at ETB and ETA receptors respectively. IRL 1620 can also discriminate between two subpopulations of ETB receptors, and in vivo IRL 1620 can significantly reduce neurological and motor deficit as well as infarct volume in a pediatric rat model of cerebral ischemia.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Takai et al (1992) A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor. Biochem.Biophys.Res.Commun. 184 953 PMID: 1315540
• Cemazar et al (2005)The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: potential for selective tumour blood flow modification. Br J Cancer 93 98 PMID: 15970923
• Cifuentes et al (2018) Neuroprotective Effect of IRL-1620, an Endothelin B Receptor Agonist, on a Pediatric Rat Model of Middle Cerebral Artery. Frontiers in Pediatrics 6 310 PMID: 30406063

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.